diabetic retinopathy semaglutide attenuates progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro - Cheng - 2025 - Diabetes, Obesity and Metabolism The Ophthalmologist | Semaglutide Blindness

A RECENT study has identified a potential link between the use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), and an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) in patients with type 2 diabetes (T2D) or those who are overweight or obese

Visible particles or debris Hold your vial or pen up to a light source and look carefully

Food and Drug Administration (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, U.S

However, major limitations of these trials are that they used advanced AID technology, included a small number of participants and had a short follow-up

This FDA approval makes Zepbound one of the few medications intended exclusively for managing weight rather than diabetes

How long does the heart rate increase last on retatrutide